- Home
- CVLT vs RYTM Comparison
CVLT vs RYTM Comparison
Compare CVLT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVLT | RYTM |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.4B |
| IPO Year | 2006 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CVLT | RYTM |
|---|---|---|
| Price | $119.48 | $100.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | ★ $183.85 | $128.69 |
| AVG Volume (30 Days) | 601.4K | ★ 658.3K |
| Earning Date | 01-27-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | ★ $1,095,835,000.00 | $174,334,000.00 |
| Revenue This Year | $19.22 | $47.40 |
| Revenue Next Year | $12.47 | $56.14 |
| P/E Ratio | $69.43 | ★ N/A |
| Revenue Growth | 22.02 | ★ 54.92 |
| 52 Week Low | $114.47 | $45.91 |
| 52 Week High | $200.69 | $122.20 |
Technical Indicators
Market Signals| Indicator | CVLT | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 38.27 | 43.27 |
| Support Level | $123.06 | $96.20 |
| Resistance Level | $127.08 | $114.00 |
| Average True Range (ATR) | 3.27 | 5.23 |
| MACD | -0.28 | -0.33 |
| Stochastic Oscillator | 9.43 | 23.07 |
Price Performance
Historical ComparisonAbout CVLT Commvault Systems Inc.
CommVault Systems Inc provides data and information management software applications and services. The firm sells software licenses and services to large global enterprises, small- and midsize businesses, and government agencies through both its salesforce and its network of reseller partners. Its software solutions include Cleanroom Recovery, HyperScale X, Air Gap Protect, Compliance, Cloud Rewind, and Clumio Backtrack. The company operates in the United States and exports to many other countries.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.